Results 41 to 50 of about 35,587 (246)
Radiology and Oncology, 2017 Identifying the early genetic drivers can help diagnose glioma tumours in their early stages, before becoming malignant. However, there is emerging evidence that disturbance of epigenetic mechanisms also contributes to cell’s malignant transformation and
Matjasic Alenka +3 more
doaj +1 more source
Case Reports in OncologyIntroduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in ...
Christian Müller +4 more
doaj +1 more source
Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma
Central Asian Journal of Medical Sciences, 2019 Objectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival.
Enkhee Ochirjav +3 more
doaj +1 more source
IDH1, Histone Methylation, and So Forth [PDF]
Cancer Cell, 2016 IDH mutants cause aberrant DNA and histone methylation and contribute to hematological and neuronal malignancies. In this issue of Cancer Cell, Inoue et al. describe a potential specific effect of IDH1 mutations that reduces Atm expression via inhibition of H3K9 demethylases, which may represent a first step toward cellular transformation.
Virginie, Penard-Lacronique +1 more
openaire +4 more sources
The Roles of IDH1 in Tumor Metabolism and Immunity
Future Oncology, 2022 IDH1 is a key metabolic enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle that can convert isocitrate into α-ketoglutarate (α-KG) and generate NADPH. The reduction of IDH1 may affect dioxygenase activity and damage the body's detoxification mechanism.
Yingqian Ni +5 more
openaire +2 more sources
Haematologica, 2020 Mutant IDH1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory AML, though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently the standard of care in older AML patients, and mIDH1 inhibitor BAY1436032. Both compounds were evaluated
Anuhar Chaturvedi, +17 more
openaire +5 more sources
IDH1 and IDH2: Not Your Typical Oncogenes [PDF]
Cancer Cell, 2010 Oncogenes usually increase their normal function when activated. However, seemingly oncogenic mutations in IDH1 and IDH2 reduce their native enzyme activity. In this issue of Cancer Cell, Ward et al. pin down a neomorphic enzyme activity as a possible oncogenic function for these alterations.
Reitman, Zachary J. +2 more
openaire +2 more sources
Expanding the spectrum of IDH1 mutations in gliomas [PDF]
Modern Pathology, 2013 Mutations in isocitrate dehydrogenase -1 or -2 (IDH1 or IDH2) are found in the majority of WHO grade II and III diffuse gliomas and secondary glioblastomas. IDH mutation screening is rapidly becoming part of the routine pathological work up of human brain tumors, providing both diagnostic and prognostic information.
Ruta, Gupta +7 more
openaire +2 more sources
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
Scientific Reports, 2023 Low-grade and secondary high-grade gliomas frequently contain mutations in the IDH1 or IDH2 metabolic enzymes that are hypothesized to drive tumorigenesis by inhibiting many of the chromatin-regulating enzymes that regulate DNA structure.
Matthew C. Garrett +18 more
doaj +1 more source
Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. [PDF]
PLoS ONE, 2012 It has been reported that IDH1 (IDH1R132) mutation was a frequent genomic alteration in grade II and grade III glial tumors but rare in primary glioblastoma (pGBM).
Wei Yan +9 more
doaj +1 more source